Data from OPTIMIST trials show SVR12 rates of 97 percent in

New Post Public Reply Private Reply Replies (0) Message Board

News Desk 2018

Apr 23, 2015 at 4:45 AM

Data from OPTIMIST trials show SVR12 rates of 97 percent in HCV patients without cirrhosis and 84 percent in HCV patients with cirrhosis

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) announces that our partner Janssen Sciences Ireland UC, today publish positive results for simeprevir, the NS3/4A protease inhibitor for the treatment of hepatitis C virus (HCV) infection, at The International Liver Congress™ 2015 of the European Association for the Study of the Liver (EASL) in Vienna. Late-breaking results from the phase III OPTIMIST-1 and OPTIMIST-2 trials highlight the clinical outcomes of simeprevir in an all-oral combination regimen in a wide range of patients with hepatitis C virus (HCV) infection. The results from the OPTIMIST-1 and OPTIMIST-2 trials are the first phase III data to be presented on simeprevir in combination with sofosbuvir (SMV/SOF) in patients with genotype 1 chronic HCV infection, both with and without cirrhosis. Sofosbuvir is a nucleotide analog NS5B polymerase inhibitor developed by Gilead Sciences, Inc. OPTIMIST-1[i] · OPTIMIST-1 is a phase III, randomized, open-label trial to investigate the efficacy and safety of the all-oral regimen of SMV/SOF among treatment-naïve and treatment-experienced genotype 1 chronic HCV infected patients without cirrhosis. The primary objective was to show superior sustained virologic response (SVR) at 12 weeks after treatment (SVR12) with twelve and 8 weeks of treatment with SMV/SOF versus a historical control (patients previously treated with approved regimens containing a direct-acting antiviral, pegylated interferon and ribavirin). · Ninety-seven (97) percent of patients treated with SMV/SOF for 12 weeks (n=150/155) achieved SVR12, which was superior to the SVR12 rate of 87 percent among the historical control. - SVR12 rates of 100 percent were seen among patients with IL28B CC genotype (n=43/43) and those with baseline NS5A and NS3 Q80K polymorphisms (n=9/9). · Patients treated with eight weeks of SMV/SOF achieved an SVR12 rate of 83 percent (n=128/155), which was not superior to the SVR12 rate of 83 percent in the historical control. - High SVR12 rates were seen among patients with baseline HCV RNA IL28B CC genotype (93 percent; n=38/41), patients with genotype 1b HCV infection (92 percent; n=36/39), and patients without baseline NS5A and Q80K polymorphisms (89 percent; n=78/88). · The most frequently reported adverse events in the 12-week and eight-week treatment arms were headache (14 and 17 percent, respectively), fatigue (12 and 15 percent, respectively) and nausea (15 and 9 percent, respectively). OPTIMIST-2[ii] · OPTIMIST-2 is a phase III, open-label, single-arm trial to investigate the efficacy and safety of SMV/SOF in treatment-naïve and treatment-experienced genotype 1 chronic HCV infected patients with cirrhosis. The primary objective was to show superior SVR12 with twelve weeks of treatment with SMV/SOF versus a historical control. · Twelve (12) weeks of treatment with SMV/SOF resulted in SVR12 rates of 84 percent (n=86/103), which was superior to the SVR12 rate of 70 percent in the historical control. · Higher SVR12 rates were seen in patients with baseline NS5A polymorphisms with or without NS3 Q80K polymorphisms (100 percent, n=13/13), patients with albumin ≥4 g/dL (94 percent; n=47/50), and treatment-naïve patients (88 percent; n=44/50). · The most common adverse events were fatigue (20 percent), headache (20 percent) and nausea (11 percent). For further information, please contact: Ola Burmark, CFO Medivir AB, mobile: +46 (0)725-480 580. Charlotte Edenius, EVP Development Medivir AB, mobile +46 (0)73-386 42 46. Medivir is required under the Securities Markets Act to make the information in this press release public. The information was submitted for publication at 10.30 CET on 23 April 2015. About Simeprevir (OLYSIO®) Simeprevir is an NS3/4A protease inhibitor which has been developed by Janssen Sciences Ireland UC in collaboration with Medivir AB. In November 2013, simeprevir was initially approved by the U.S. Food and Drug Administration, and in May 2014, it was granted marketing authorisation by the European Commission. Subsequent marketing authorisations have followed in several other countries around the world. Indications vary by market. Janssen is responsible for the global clinical development of simeprevir and has exclusive, worldwide marketing rights, except in the Nordic countries. Medivir AB retains marketing rights for simeprevir in these countries under the marketing authorisation held by Janssen -Cilag International NV. About Medivir Medivir is a research based pharmaceutical company with a research focus on infectious diseases and oncology. We have a leading competence within protease inhibitor design and nucleotide/nucleoside science and we are dedicated to develop innovative pharmaceuticals that meet great unmet medical need. Our commercial organization provides a growing portfolio of specialty care pharmaceuticals on the Nordic market. Medivir is listed on the Nasdaq Stockholm Mid Cap List. ---------------------------------------------------------------------- [i] A Phase 3, randomised, open-label study to evaluate the efficacy and safety of 12 and 8 weeks of treatment with simeprevir plus sofosbuvir in treatment -naïve and -experienced patients with chronic HCV genotype 1 infection without cirrhosis: The OPTIMIST-1 study. Abstract presented at The International Liver Congress™ 2015. [ii] A Phase 3, open-label, single-arm study to evaluate the efficacy and safety of 12 weeks of simeprevir plus sofosbuvir in treatment-naïve or –experienced patients with chronic hepatitis c virus genotype 1 infection and cirrhosis: The OPTIMIST-2 study. Abstract presented at The International Liver Congress™ 2015.

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Nielsen's $1.4B Notes to Fuel Bold DoubleVerify Buy

Reading Between the Financial Lines Nielsen's latest move throws a hefty $1.4 billion worth of senior secured notes into the market, aimed at scooping up DoubleVerify in a play that’s as daring as it is dicey. It's the kind of gamble you discuss with your coffee buddy, sipping something strong enough to wake the dead, and exactly the kind of deal that gets seasoned...

Victaulic's Top Honors for Supporting Reservists

Victaulic's latest accolade isn't just some badge to hang on the wall. This 5 STAR rating from Friendly Forces is a testament to a rock-solid commitment that goes way beyond lip service. It's about real backing for the Reservists who often juggle dual lives—combining military demands with civilian careers. Backing Reservists: Victaulic Steps Up Big When you look at how...

Total Wine CEO Pushes Congress for THC Regulation

Prohibition or Regulation? The Battle Over THC When it comes down to it, the old dance of prohibition versus regulation is heating up yet again. We're not talking about alcohol this time around but low-dose hemp-derived THC-infused beverages. The folks over at Total Wine & More, with CEO Ryan Ross leading the charge, are shouting from the rooftops for regulation. And,...

Align's Innovative Transporter Revolutionizes Engine Assembly

Align's Game-Changer in Engine Manufacturing Let's face it, the world of heavy-duty equipment isn't always filled with breakthroughs. But every once in a while, a game-changer rolls off the line, and that's what's happening with Align Production Systems. They've crafted a custom omnidirectional transporter that does more than just move bulky engine assemblies; it...

Travel Deal Tuesday Offers Major Savings Opportunities

Travel aficionados, pay attention! Hopper's Travel Deal Tuesday is back, and if there's any day to catch a break on your jet-setting costs, it's December 1st. Travel costs have been on a steep incline, with domestic airfares up a whopping 40% over the past year. This year marks the tenth anniversary of Travel Deal Tuesday, and Hopper is pulling out all the stops to save...

EASEL 360: Reinventing Comfort in Painting Tools

Artists, listen up—particularly those who are tired of the usual rigmarole that comes with traditional easels. There's a fresh tool coming down the pike, and it's set to make your painting experience a whole lot friendlier. Meet the EASEL 360, a patent-pending innovation birthed by two inventive folks from Streetsboro, Ohio. No longer will you have to contort yourself...

FIS Under Investigation: Legal Woes Hit Shareholders

When Forecasts Falter: A Reality Check for FIS Investors You ever get the feeling a company is just a bit too optimistic? Well, Fidelity National Information Services, Inc. (NYSE: FIS) might've been playing that game up until its recent fiscal hiccup. The mess started on November 4, 2026, when FIS decided to slash its fiscal 2026 adjusted EPS outlook. From a Wall Street...

Call for Biotech Shift: Scarcity Drives Urgency

The Cry for an Industrial Biotech Shift Alright, folks, here's the deal: James Michael Matthew is waving a red flag. He's saying it's time to overhaul our approach to industrial biotechnology. Why? Because we're up against some big-time raw material shortages. Matthew's call isn't just a whisper in the wind; it's a siren echoing through an industry teetering on the edge...

Peanuts and Diabetes: A Surprising Health Link

A Nutty Approach to Diabetes Prevention Who would've thought peanuts could pack such a punch against diabetes? Amid the usual suspects of healthy foods, it's these humble legumes that are making headlines. The Peanut Institute, backed by fresh research, is shining a spotlight on their potential role in preventing type 2 diabetes, a disease that's affecting roughly 40...

Honeywell Aerospace Faces Litigation Amid Stock Decline

The Tumbling Honeywell Aerospace Saga Some days, stocks have you feeling like a cat stranded in a tree, and right now, Honeywell Aerospace (NASDAQ:HONA) is very much that cat—with branches breaking beneath it. Investors have been tossed into the fray after the company’s stock nosedived over 23% following ominous earnings and legal revelations. It's a market story...